menu

MYR Pharmaceuticals — Treatment of HBV & HDV Infections

Career opportunities — Join our team! Privacy Policy

Company

HomeAboutCompany
HomeAboutCompany

Company

What are we doing?

MYR Pharmaceuticals is headquartered in Bad Homburg (Germany). The company started operations in 2011 and is supported by venture capital investors such as the HighTech-Gründerfonds and Maxwell Biotech Venture Fund as well as various business angels. We are focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D virus infections. MYR’s lead compound Bulevirtide (formerly known as Myrcludex B), a first-in-class entry inhibitor for the treatment of chronic hepatitis B and D infections, progresses into a phase III clinical study for the indication of chronic HDV infection. The technology was originally developed by Prof. Dr. Stephan Urban of the University of Heidelberg (Germany) and by Prof. Dr. Phillipe Gripon of INSERM (France) and represents one the most clinically advanced novel approaches for the treatment of hepatitis B and D.

Numbers and facts

  • Employees:  > 20
  • Founded: 2011
  • Patients treated with Bulevirtide: >600
  • Conducted studies: 6

Our values

  • At MYR we fully dedicate our work to bring benefit to Hepatitis D patients targeting a disease with high unmet medical need
  • Strong teamwork is key to our success and the fundament of our growth
  • Open communication and international, friendly and respectful atmosphere

Highlights

MYR Pharmaceuticals has announced highly positive results from its MYR 202 clinical trial, a Phase 2b study investigating Bulevirtide in chronic hepatitis delta infection. After 24 weeks of treatment Bulevirtide demonstrated an excellent safety profile with no drug-related serious adverse events during the treatment period of 24 weeks and no treatment discontinuations due to the study medication. The primary endpoint, undetectable HDV RNA or decline of ≥2 log IU/ml HDV RNA to baseline, was met for all doses of Bulevirtide.